Latest updates to the ESMO bone health guidelines

Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004

CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers

AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC

Estimate of the 2-year oncology workload generated by each new patient: A real-world study

Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC

Impact of COVID-19 pandemic on cancer care: A global collaborative study

MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer

LungART: Radiotherapy after surgery for patients with non small cell lung cancer

Personalised molecularly matched therapies for carcinomas of unknown primary

SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer